Archive
1250 articles, sorted by publication time.
Researchers transformed engineered bacteria that temporarily colonize the gut into glucose sensors, releasing therapeutic proteins when blood sugar rises; animal studies covered metabolic and complication-related markers, but safety and efficacy in humans remain open questions.
Moderna’s mFLUSIVA was approved for adults aged 50 and older; a large trial showed an approximately 27% relative reduction in influenza cases, but its benefit in people aged 65 and older still requires confirmation through postmarketing research.
Antiretroviral drugs, two broadly neutralizing antibodies, and a CCR5-blocking antibody worked together to keep all eight infant macaques free of viral rebound after treatment was stopped. The findings point to a possible window for eradicating infection early, although multiple barriers remain before clinical use in newborns.
Encapsulated engineered human cells can produce leptin on demand, helping rodents and nonhuman primates adapt to new light-dark cycles; the findings advance controllable cell therapy into large animals, but safety and engineering challenges remain before it can be used by travelers.
U.S.-based Intermountain Health has introduced the FDA-cleared OCT-assisted system at two hospitals, allowing surgeons to examine suspicious tissue before breast-conserving surgery is complete; a clinical trial showed it can reduce some positive margins but cannot replace pathological diagnosis.
The new flagship centre will connect laboratories, hospitals and the biotech cluster while supporting a programme to accelerate late-stage medicines; the investment also means GSK will exit its existing Stevenage R&D site by 2029.
The research team connected geometric deep learning with high-throughput experiments into a single screening pipeline, identifying 43 new candidate binding proteins and revealing how adjacent zinc fingers influence degradation; however, there is still some distance between “can bind” and a safe, selective drug.
The collaboration advances preliminary TROP2 and PTEN signals toward assay validation, with the aim of establishing patient-selection criteria for Reqorsa clinical trials; however, the existing associations still require confirmation with prospective clinical data.
An Oxford University research team has administered Moderna’s mRNA-4194 to the first participant in an attempt to prompt the immune system to eliminate precancerous cells early; at this stage, this first-in-human study is primarily assessing safety and immune responses and cannot yet demonstrate that the vaccine can prevent cancer.
Natural inhibitory proteins in western diamondback rattlesnake blood worked together in mouse experiments to suppress bleeding, tissue damage, and death, with roughly ten times the potency by weight of the comparator antivenom; however, the strategy currently addresses only some toxins and still faces extensive testing before it can be used in humans.
A new platform delivers gene knockout, base editing, and epigenetic silencing into hard-to-engineer primary monocytes, macrophages, and dendritic cells, while large-scale screening identifies TNFAIP3; the work remains at the laboratory stage, with multiple hurdles still standing between it and clinical manufacturing and safety validation.
A 550-micrometer magnetically controlled carrier first protects its drug payload with an acid-resistant coating, then releases platelet membrane-coated nanoparticles in the intestinal environment; in vitro models showed improved retention and cancer-killing effects, but animal validation and clinical application remain a long way off.